The Company’s 2025 financial guidance reflects its evolution to a fully integrated commercial-stage biotechnology company independently launching its first medicine, TRYNGOLZA, and advancing commercialization efforts for multiple additional upcoming planned launches. As a result, the Company expects to earn substantial revenue from numerous diverse sources, with a shift toward increasing commercial revenue. Additionally, the Company expects a modest increase in its non-GAAP operating expenses in line with its plan to invest in the Company’s independent launches and advance its wholly owned pipeline of innovative medicines. The Company expects that these investments will enable Ionis to deliver accelerating value. Sees operating loss on a non-GAAP basis less than $495M; Cash, cash equivalents and short-term investments ~$1.7B….
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals reports Q4 EPS (66c), consensus (84c)
- Is IONS a Buy, Before Earnings?
- Arrowhead price target lowered to $38 from $51 at B. Riley
- Ionis ‘remains confident in pelacarsen’ after Novartis update on Phase 3 timing
- Ionis unveils pipeline plan for 2025, expects 4 independent product launches